Revenue has remained flat at $18,000 per quarter for ten consecutive periods, while R&D expenses escalated to $1.0 million in 2026Q1, driving a negative operating margin of 88.5%.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Sales/Revenue | 72.1K | 72.1K | 72.1K | 72.1K | 72.1K | 71.26K | 0 | 40.57K | 0 | 847.41K | -669.48K | -145.19K | -107.11K | 105.52K | 0 | 0 |
| Revenue Growth % | 0% | 0% | 0% | 0% | 1.18% | - | -100% | - | -100% | 226.58% | -361.12% | -35.54% | -201.51% | - | - | - |
| Cost of Goods Sold | 309.09K | 886.06K | 5.84K | 5.84K | 5.84K | 5K | 0 | 27.39K | 17.55K | 0 | 0 | 0 | -127.68K | 104.9K | 0 | 0 |
| COGS % of Revenue | - | 1228.89% | 8.1% | 8.1% | 8.1% | 7.02% | - | 67.51% | - | - | - | - | 119.2% | 99.41% | - | - |
| Gross Profit | -236.99K | -813.96K | 66.26K | 66.26K | 66.26K | 66.26K | 0 | 13.18K | -17.55K | 847.41K | -669.48K | -145.19K | 20.57K | 625 | 0 | 0 |
| Gross Margin % | -328.69% | -1128.89% | 91.9% | 91.9% | 91.9% | 92.98% | - | 32.49% | - | 100% | 100% | 100% | -19.2% | 0.59% | - | - |
| Gross Profit Growth % | - | -1328.35% | 0% | 0% | 0.01% | - | -100% | 175.11% | -102.07% | 226.58% | -361.12% | -805.98% | 3190.4% | - | - | - |
| Operating Expenses | 4.54M | 3.47M | 4.77M | 3.92M | 3.69M | 2.81M | 2.2M | 943.59K | 459.83K | 490.87K | 443.49K | 264.31K | 269.44K | 72.61K | 39.45K | 49.8K |
| OpEx % of Revenue | - | 4808.06% | 6618.34% | 5439.32% | 5123.19% | 3943.93% | - | 2325.88% | - | 57.93% | -66.24% | -182.05% | -251.54% | 68.81% | - | - |
| Selling, General & Admin | 1.96M | 2.15M | 2.4M | 3.08M | 2.43M | 2.27M | 2.18M | 864.18K | 459.83K | 313.37K | 300.99K | 167.7K | 269.44K | 72.61K | 39.45K | 49.8K |
| SG&A % of Revenue | - | 2978.61% | 3333.89% | 4267.24% | 3366.74% | 3178.59% | - | 2130.15% | - | 36.98% | -44.96% | -115.51% | -251.54% | 68.81% | - | - |
| Research & Development | 2.58M | 2.16M | 2.37M | 845.09K | 1.29M | 693.91K | 26.25K | 63.47K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 2996.91% | 3284.45% | 1172.08% | 1784.19% | 973.72% | - | 156.44% | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -841.76K | 0 | 0 | -20K | -148.5K | 0 | 15.94K | 314.61K | 177.5K | 142.5K | 96.61K | 0 | 0 | 0 | 0 |
| Operating Income | -4.78M | -4.28M | -4.71M | -3.86M | -3.63M | -2.74M | -2.2M | -930.4K | -594.24K | -470.39K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.8K |
| Operating Margin % | -6631.16% | -5936.95% | -6526.44% | -5347.41% | -5031.28% | -3850.95% | - | -2293.38% | - | -55.51% | 58.8% | 149.58% | 232.34% | -68.22% | - | - |
| Operating Income Growth % | - | 9.03% | -22.05% | -6.28% | -32.19% | -24.65% | -136.64% | -56.57% | -26.33% | -19.49% | -81.27% | 12.74% | -245.72% | -82.49% | 20.8% | - |
| EBITDA | -4.77M | -4.27M | -4.7M | -3.63M | -3.91M | 4.19M | -2.4M | -950.37K | -576.69K | 356.54K | 325.66K | -24.85K | -121.19K | -71.99K | -39.45K | -49.8K |
| EBITDA Margin % | -6615.51% | -5921.09% | -6517.86% | -5029.28% | -5416.2% | 5872.56% | - | -2342.59% | - | 42.07% | -48.64% | 17.11% | 113.14% | -68.22% | - | - |
| EBITDA Growth % | 2.7% | 9.16% | -29.6% | 7.14% | -193.31% | 274.59% | -152.22% | -64.8% | -261.75% | 9.48% | 1410.71% | 79.5% | -68.35% | -82.49% | 20.8% | - |
| D&A (Non-Cash Add-back) | 11.29K | 11.44K | 6.18K | 0 | 0 | 0 | 0 | 0 | 17.55K | 0 | 719.32K | 192.33K | 127.68K | 0 | 0 | 0 |
| EBIT | -4.8M | -4.19M | -4.39M | -3.63M | -3.91M | 4.19M | -2.4M | -950.37K | -969.46K | 356.54K | -393.66K | -217.17K | -248.87K | -71.99K | -39.45K | -49.8K |
| Net Interest Income | 132.19K | 156.61K | 328.08K | 393.66K | 70.44K | -1.83K | -257.72K | -50.73K | 0 | 0 | 49.84K | 40.34K | 13.81K | 625 | 0 | 0 |
| Interest Income | 170.8K | 193.91K | 333.17K | 398.53K | 72.64K | 1.21K | 11.54K | 12.2K | 4.22K | 20.48K | 49.84K | 40.34K | 20.57K | 625 | 0 | 0 |
| Interest Expense | 38.61K | 37.3K | 5.08K | 4.87K | 2.2K | 3.04K | 269.27K | 62.93K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -62.18K | 52.96K | 312.81K | 224.51K | -279.73K | 6.93M | -464.55K | -82.89K | -375.22K | 826.92K | -719.32K | -192.33K | 0 | 104.9K | 0 | 0 |
| Pretax Income | -4.84M | -4.23M | -4.39M | -3.63M | -3.91M | 4.18M | -2.67M | -1.01M | -969.46K | 356.54K | -1.11M | -409.5K | -376.55K | 32.91K | -39.45K | -49.8K |
| Pretax Margin % | -6717.4% | -5863.5% | -6092.59% | -5036.04% | -5419.25% | 5868.3% | - | -2497.71% | - | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 24.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.59% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -4.84M | -4.23M | -4.39M | -3.7M | -3.91M | 3.9M | -3.04M | -1.01M | -969.46K | 356.54K | -1.11M | -409.5K | -376.55K | 32.91K | -39.45K | -49.8K |
| Net Margin % | -6717.4% | -5863.5% | -6092.59% | -5132.57% | -5420.86% | 5477.86% | - | -2497.71% | - | 42.07% | 166.24% | 282.05% | 351.54% | 31.19% | - | - |
| Net Income Growth % | -4.77% | 3.76% | -18.7% | 5.32% | -200.12% | 228.52% | -199.77% | -4.52% | -371.91% | 132.03% | -171.79% | -8.75% | -1244.14% | 183.43% | 20.8% | - |
| Net Income (Continuing) | -4.84M | -4.23M | -4.39M | -3.63M | -3.91M | 4.16M | -2.67M | -1.01M | -969.46K | 356.54K | -1.11M | -409.5K | -376.55K | 32.91K | -39.45K | -49.8K |
| Discontinued Operations | 0 | 0 | 0 | -69.6K | -1.16K | -253.37K | -371.25K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.30 | -7.50 | -17.85 | -18.00 | -25.65 | 19.50 | -35.25 | -18.60 | -14.85 | 7.50 | -16.65 | -6.00 | -5.85 | 0.76 | -0.97 | -1.22 |
| EPS Growth % | 56.85% | 57.98% | 0.83% | 29.82% | -231.54% | 155.32% | -89.52% | -25.25% | -298% | 145.05% | -177.5% | -2.56% | -869.23% | 178.73% | 20.79% | - |
| EPS (Basic) | - | -7.50 | -17.85 | -18.00 | -25.65 | 19.80 | -35.25 | -18.60 | -14.85 | 7.50 | -16.65 | -6.00 | -5.85 | 0.76 | -0.97 | -1.22 |
| Diluted Shares Outstanding | 913.95K | 558.82K | 245.36K | 205.32K | 152.28K | 127.9K | 87.94K | 56.15K | 65.47K | 69.44K | 66.93K | 67.44K | 63.89K | 43.25K | 40.84K | 40.84K |
| Basic Shares Outstanding | 913.95K | 558.82K | 245.36K | 205.32K | 152.28K | 126.49K | 87.94K | 56.15K | 65.47K | 66.78K | 66.93K | 67.44K | 63.89K | 43.25K | 40.84K | 40.84K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Dilutive financing dependency
According to the provided quarterly income statements, SILO has maintained a flat revenue profile of $18,000 per quarter for ten consecutive periods, indicating that the company currently lacks a commercialized product engine and remains entirely dependent on non-recurring, grant-based or transactional inflows for its top-line figures.
The absence of revenue growth suggests that the company is not yet transitioning toward a commercial stage, but rather remains in a purely developmental phase. Investors should interpret this stability as a lack of operational momentum, as the current revenue stream does not reflect market adoption or product scalability.
As reported in financial filings, SILO's gross margin has experienced extreme fluctuations, swinging from a positive 91.9% in several quarters to a deeply negative 13.8% in 2026Q1, which highlights the structural instability inherent in a firm expensing clinical trial costs without offsetting commercial sales.
These margin swings appear to be driven by the timing of laboratory and formulation expenditures rather than pricing power or cost efficiencies. The negative margins observed in recent periods suggest that the company is currently absorbing significant clinical trial overhead, which will likely continue to pressure profitability until a commercial pivot occurs.
Based on the income statement data, R&D expenses have trended upward to $1.0 million in 2026Q1, reflecting the company's intensified focus on clinical trial milestones which necessitates a high level of ongoing investment in research and regulatory compliance activities.
The concentration of spending in R&D indicates that management is prioritizing the advancement of its CNS-homing peptide platform over operational leaness. This cost structure warrants further investigation, as the inability to scale SG&A efficiency while R&D costs rise suggests a widening gap between capital deployment and potential commercial viability.
Analysis of the income statement reveals that SILO's operating losses have consistently exceeded $1 million in recent quarters, creating a precarious financial position that suggests the company may face significant liquidity constraints if clinical milestones are not met before the current cash reserves are exhausted.
Short-term observers should monitor the relationship between the rising R&D spend and the limited cash runway, as the current burn rate appears unsustainable without external capital. The reliance on dilutive financing to fund these losses remains a primary risk factor that could materially impact shareholder value in the near term.
Quick answers to the most common questions about buying SILO stock.
For fiscal year 2025, Silo Pharma, Inc. (SILO) reported total revenue of $0.1M.
Silo Pharma, Inc. (SILO) reported a net loss of $4.2M for the fiscal year ending 2025.
Silo Pharma, Inc. (SILO) reported an operating income of $-4.3M, resulting in an operating profit margin of -5937.0%. This margin reflects the operational efficiency of the business before interest and taxes.
Silo Pharma, Inc. (SILO) generated $-0.8M in gross profit for the year, representing a gross profit margin of -1128.9%. This demonstrates the company's core pricing power and production efficiency.